Hypertrophic scarring affects a large proportion of patients following burns, trauma, or surgery and arises from prolonged fibroblast hyperactivity and excessive extracellular matrix accumulation.
CollPlant (CLGN) is now moving towards clinical trials and scaling and optimizing its manufacturing to ensure readiness for the upcoming clinical trials REHOVOT, Israel, Sept. 30, 2025 /PRNewswire/ -- ...
Please provide your email address to receive an email when new articles are posted on . Two calcium hydroxyapatite-based derma fillers were compared. Filler suspended in carboxymethylcellulose induced ...
CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies ...
Michael Freeman is the founder of The Skin Centre, a private dermatology practice which also offers dermal fillers. Fillers are now one of the most common non-surgical cosmetic procedures. Adding ...
RIT biomedical engineering researchers identify a protein that can reduce fibrosis and slow disease progression.
CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results